Erratum for vol. 101, p. 1422

In the article by Ratzinger et al entitled “Differential CD52 expression by distinct myeloid dendritic cell subsets: implications for alemtuzumab activity at the level of antigen presentation in allogeneic graft-host interactions in transplantation,” which appeared in the February 15, 2003, issue of Blood (Volume 101:1422-1429), there was an incorrect dosage in the third paragraph under “Cell purification and generation of DCs.” The correct dosage of FLT-3 ligand is 50 ng/mL.